Karyopharm Therapeutics Inc (KPTI)
1.13
+0.05
(+4.63%)
USD |
NASDAQ |
May 03, 16:00
1.12
-0.01
(-0.88%)
After-Hours: 20:00
Karyopharm Therapeutics Research and Development Expense (Annual): 138.75M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 138.75M |
| December 31, 2022 | 148.66M |
| December 31, 2021 | 160.84M |
| December 31, 2020 | 150.81M |
| December 31, 2019 | 122.34M |
| December 31, 2018 | 161.37M |
| December 31, 2017 | 107.27M |
| Date | Value |
|---|---|
| December 31, 2016 | 86.94M |
| December 31, 2015 | 97.74M |
| December 31, 2014 | 60.13M |
| December 31, 2013 | 28.45M |
| December 31, 2012 | 14.10M |
| December 31, 2011 | 8.623M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
122.34M
Minimum
2019
160.84M
Maximum
2021
144.28M
Average
148.66M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Geron Corp | 125.05M |
| Arbutus Biopharma Corp | 73.70M |
| Verastem Inc | 61.36M |
| Actinium Pharmaceuticals Inc | 38.67M |
| Chimerix Inc | 68.79M |